GlucoTrack (GCTK) Appoints John Ballantyne to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- This is Morgan Stanley's only preferred sportswear stock
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
September 3, 2024 9:00 AM EDTBiotech veteran joins Glucotracks Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (Glucotrack or the Company), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately.
We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors,"... More
